NEUmiRNA featured on MedWatch: “RNA startup from Copenhagen begins hunting for large capital raising”

Neumirna Therapeutics has named Andreas Wallnöfer as an independent member of its Board of Directors.

With a new CEO in place, Sunstone-backed Neumirna aims to land a three-digit million sum in the first half of 2024.

This grant from the Innovation Fund Denmark (IFD) will help us in further establishing our drug discovery pipeline, aimed at developing disease-modifying RNA Therapies for Parkinson's Disease at NEUmiRNA, in collaboration with Aalborg University and the Center for RNA Medicine (CRM).